(type VI) were unaffected by lithium. These and prior results indicate that lithium targets a part of the AA cascade that involves cPLA 2 and COX-2. This effect may contribute to lithium's therapeutic action in bipolar disorder.
Introduction
Although lithium has been used for over 50 years to treat bipolar disorder, 1 the basis of its therapeutic effect remains unclear. Several molecular targets of lithium have been suggested. They involve guanine nucleotide binding protein, adenylyl cyclase, protein kinase C isoenzymes, the phosphoinositide cycle, and balance of neurotransmitter signaling. [2] [3] [4] Lithium also has been suggested to be neuroprotective, by increasing expression of the anti-apoptotic protein Bcl-2 and decreasing expression of the pro-apoptotic p53 and Bax in vitro. 5 On the other hand, the arachidonic acid (AA, 20:4 n-6) cascade, which plays a key role in brain signaling, [6] [7] [8] could represent a target of lithium and other mood-stabilizers. Indeed, previous reports suggest a role for PGE 1 , a metabolite of dihomogamma-linolenic acid, in affective disorders, 9 ,10 but the exact mechanism by which the AA cascade is targeted has not been thoroughly investigated. This cascade involves phospholipase A 2 (PLA 2 )-mediated release from phospholipids of the polyunsaturated fatty acid (PUFA), AA, and its conversion to bioactive eicosanoids. [11] [12] [13] In this regard, we reported that chronically administered lithium in rats decreased by 80% the turnover rate of AA, regulated by PLA 2 , within the stereospec- ifically numbered (sn)-2 position of brain phospholipids, without affecting palmitic or docosahexaenoic acid turnover. 14, 15 Decreased AA turnover was accompanied by reduced activity of PLA 2 not caused by direct enzyme inhibition by lithium, 16 and by reduced mRNA and protein levels of the AA-selective cytosolic PLA 2 (cPLA 2 , type IV). 17 These initial results suggested that lithium might target the AA cascade.
AA can be converted to prostaglandin H 2 (PGH 2 ), the common precursor for biologically active eicosanoids, by either cyclooxygenase (COX, prostaglandinendoperoxide synthase)-1 or -2.
18 COX-1 is constitutively expressed and is thought to produce eicosanoids for normal physiological function, whereas COX-2 is induced in pathological conditions, often in response to proinflammatory agents. 19 COX-2 is the predominant isoform in brain and spinal cord, where it is considered involved in synaptic signaling, 20 cerebral blood flow, 21 and behavior. 22 The aim of this study was to determine whether chronic oral administration of LiCl has a downstream effect on the AA cascade. We therefore measured brain mRNA, protein, and enzyme activity levels of COX enzymes, as well as the concentration of prostaglandin E 2 (PGE 2 ). While PGE 2 is not the only prostaglandin present in brain, it does represent a major product of the cyclooxygenase reaction and plays a key role in sleep regulation, which is altered in bipolar disorder. 23 We also measured the protein level of the intracellular Ca 2+ -independent iPLA 2 (type VI), to see if lithium affected brain phospholipases generally or cPLA 2 specifically.
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Materials and methods
Lithium administration
The study conformed to the Guideline for the Care 14 Control rats were given lithium-free chow under parallel conditions. Rats used for PGE 2 measurements were killed with sodium pentobarbital (50 mg kg −1 i.p.), then subjected to head-focused microwave irradiation (5.5 kW, 3.4 s, Cober Electronics, Stanford, CT, USA). Rats used for RNA, protein or enzyme analysis were killed by carbon dioxide inhalation, and then decapitated. Brains were rapidly excised, frozen in −50°C 2-methylbutane, and stored at −80°C until use.
Measurement of lithium concentration in brain and plasma
Brain and plasma concentrations of lithium were quantified using a graphite furnace Zeeman 5100 atomic absorption spectrometer (Perkin-Elmer, Norwalk, CT, USA), at a wavelength of 670.8 nm. Frontal cortex samples (50 mg) were digested overnight in 0.5 ml concentrated HNO 3 at 60°C and then diluted to 5 ml total volume with 0.2% HNO 3 . Plasma samples were initially diluted 3-fold with 0.2% HNO 3 . Brain and plasma samples were further diluted as necessary to keep the lithium concentration below the highest standard.
RNA isolation and RT-PCR
Total RNA was isolated with a Qiagen RNeasy Maxy kit (Qiagen, Valencia, CA, USA). Two g of total RNA were reverse transcribed using a RETROscript kit (Ambion, Austin, TX, USA). Half of each RNA sample was incubated similarly in the absence of reverse transcriptase to test for genomic DNA contamination. PCR amplification was performed using specific oligonucleotide primers for COX-1 (forward: 5Ј-CCTTC TCCAACGTGAGCTACTA-3Ј, reverse: 5Ј-GTGGAGAA GAGCATCAGACC-3Ј, 486 bp), 24 and COX-2 (forward: 5Ј-ACTTGCTCACTTTGTTGAGT3Ј; reverse: 5Ј-TTGA TTAGTACTGTAGGGTT-3Ј, 581 bp). 25 Specific G3PDH primers (983 bp, Clontech, Palo Alto, CA, USA) were used as an internal control to normalize the sample amounts. After an initial 5-min denaturation at 95°C, the DNA was amplified for 30 cycles of 20 s denaturation at 94°C, primer annealing at 55°C for 30 s, and extension at 72°C for 40 s, with a final extension at 72°C for 5 min. Agarose gels (1.2%) were stained with ethidium bromide and the bands were quantified by AlphaEase Stand Alone software (Alpha Innotech, San Leandro, CA, USA). Integrated densities were normalized to G3PDH values to yield a semi-quantitative assessment of individual transcript levels. Preliminary experiments confirmed that the PCR conditions and the image analysis system were in the linear range of detection.
Western blot analysis
Brains were homogenized and Western blot analysis carried out as previously reported, 17 using primary antibodies for COX-1 (polyclonal, 1:1000), COX-2 (polyclonal, 1:2000), iPLA 2 , type VI (monoclonal, 1:2000) (Cayman Chemicals, Ann Arbor, MI, USA), or actin (1:10 000, Santa Cruz Biotechnology). For COX-1, COX-2, and actin a secondary antibody conjugated with horseradish peroxidase (HRP, 1:1000, 1:5000, and 1:10 000, respectively, Bio-Rad, Hercules, CA, USA) was used. For iPLA 2 a biotinylated secondary antibody (1:2000) followed by HRP (1:1000, Vector, Burlingame, CA, USA) was used. Immunoblots were visualized on X-ray film by chemiluminescence reaction (Pierce, Rockford, IL, USA), and image analysis was performed on optical density-calibrated images by AlphaEase Stand Alone software (Alpha Innotech).
PGE 2 enzyme immunoassay
Levels of PGE 2 were determined in microwaved brain extracts. Brains were weighed, then extracted in 18 volumes of hexane: 2-propanol (3:2, by volume) using a glass Tenbroeck homogenizer. The prostaglandins were purified from the lipid extract using a C 18 Sep-Pak cartridge (Waters, Milford, MA, USA) by the method of Powell. 26 The concentration of PGE 2 was determined using an enzyme-linked immunosorbent assay (ELISA) (Oxford Biomedical, Oxford, MI, USA).
Measurement of COX activity COX activity was determined by the method of Taniguchi et al 27 with modifications. One half of a brain was homogenized in 3 ml of lysate buffer (10 mM Tris-HCl, pH 7.8, containing 1% Nonidet P-40, 0.15 M NaCl, and 1 mM EDTA), then chilled on ice for 30 min and centrifuged at 4000 rpm for 25 min. The supernatant was diluted 1:10 with lysate buffer. To 500 l of the diluted sample was added 60 l of lysate buffer containing 10 mM phenol, 18.2 mM l-epinephrine, 4.6 mM glutathione, and 9.3 M hematin. To determine whether LiCl directly inhibited COX activity, the reaction was carried out on brain homogenates from control animals in the presence or absence of 1 mM LiCl. The mixture was chilled on ice for 10 min, then 60 l of lysate buffer containing 1 mM AA was added, and the mixture was incubated at 37°C for 10 min. The reaction was terminated by adding 250 l of 1 M HCl. PGE 2 was extracted by ethyl acetate 27 and determined using a PGE 2 immunoassay kit (Cayman). A sample not allowed to react with AA was prepared and assayed in the same manner, and used for blank determination. The intra-and inter-assay variability for this kit was Յ 10%. Cross-reactivity with PGE 1 was 18.7% and with PGE 3 was 43%.
Statistical analysis
Results are expressed as means ± SEM. Statistical analysis was performed using unpaired Student's ttests and significance was taken as P Յ 0.05.
Results
Time course of lithium concentration in plasma and brain
Lithium was not detected in plasma or brain of control rats fed a lithium-free diet. Lithium concentration, expressed as the mean ± SEM of four independent samples, was 0.79 ± 0.07 mM in the brain and 0.74 ± 0.03 mM in the plasma of rats fed lithium for 6 weeks. The brain lithium concentration became equivalent to the plasma concentration after 14 days of daily oral administration, giving an approximate half-life of 1 week to reach a steady state in brain. 28 
Lithium downregulates COX-2 but not COX-1 protein
No statistically significant difference was observed by RT-PCR in brain mRNA levels of COX-1 or COX-2, normalized to the G3PDH mRNA level, between lithiumtreated and control rats (n = 10) (Figure 1a, b) . In Western blots, the COX-2 antibody detected a prominent (Figure 2a ). In the lithium-treated group, the COX-2 protein level was decreased by 31.4 ± 5.1% (P Ͻ 0.01, n = 12) compared to the control level (Figure 2b) . Thus, chronic lithium downregulated COX-2 post-transcriptionally. In contrast, the COX-1 protein level was not changed by chronic lithium. There also was no decrease in the protein level of the Ca 2+ -independent iPLA 2 (type VI) (Figure 3 ), suggesting that chronic lithium specifically affects cPLA 2 , 17 as well as COX-2 protein (Figure 2 ).
Lithium decreases brain PGE 2 concentration and COX enzyme activity
To see if the observed reduction of COX-2 protein was accompanied by a decrease in PGE 2 , an AA metabolite produced by COX-2, we measured PGE 2 in brains of control and lithium-treated rats. The brain PGE 2 con- centration was significantly decreased by 49% in the lithium-treated rats compared to controls (Table 1) . COX enzyme activity was decreased significantly in brain tissue of lithium-treated compared to control rats (91.9 ± 5.6 vs 182.2 ± 6.0 pg PGE 2 min −1 g −1 cytosolic protein, n = 3, P Ͻ 0.01) (Figure 4) . Preincubation of control samples with 1 mM LiCl did not change COX activity (201.7 ± 11.1 pg min (Figure 4 ), indicating that lithium did not directly inhibit COX-2, but reduced its activity by a posttranscriptional or post-translational mechanism. In a separate set of experiments, control cytosolic fraction was incubated with 1 mM LiCl (therapeutic concentration), and then assayed for COX activity to test for direct inhibition. COX activity is expressed as pg PGE 2 min −1 g −1 cytosolic protein. Data are means ± SEM of three independent samples for each group. **P Ͻ 0.01.
Discussion
This study supports our hypothesis that the brain AA cascade is a target for lithium. In addition to reducing AA turnover and cPLA 2 expression as previously reported, [14] [15] [16] [17] we now show that chronic lithium reduces COX-2 protein and its enzymatic activity but not its mRNA level in rat brain. Chronic lithium also reduces the basal brain concentration of PGE 2 , a bioactive metabolite of AA produced via COX, thus downregulating an important downstream step in the AA cascade. Lithium's effects on the cascade appear to be selective, as brain iPLA 2 and COX-1 protein levels were unchanged by chronic lithium, and the mRNA level for iPLA 2 is reported to be unaffected. 17 The selective effect of lithium on cPLA 2 and COX-2 may be related to the functional coupling of these enzymes. Studies in isolated cells indicate that labeled AA taken up from the medium cannot be converted to eicosanoids by COX unless it is first esterified into phospholipids and then released by PLA 2 . 29 Both cPLA 2 and COX-2 are localized at the nuclear envelope and perinuclear area, allowing them to act in a coordinated fashion, 30 and their genes are adjacent to each other on chromosome 1. 31 The hypothesis that lithium targets cPLA 2 and COX-2 function is consistent with evidence in rats that lithium also reduces the brain concentration of arachidonoyl-CoA, the precursor pool for AA reincorporation into phospholipids.
14 Furthermore, valproic acid, also a mood-stabilizer, reduces AA turnover in brain phospholipids as well as the plasma AA concentration in unanesthetized rats. 32 Valproic acid also is reported to reduce levels of lipoxygenase and COX bioactive pro-ducts in rat platelets. 33 One way to test whether lithium's targeting of the AA cascade is relevant to its therapeutic effect would be to treat bipolar patients with a COX-2 inhibitor. 34 In this regard, aspirin, a nonselective COX inhibitor, is reported to have a beneficial mood-modulating effect when used for antithrombosis. 35 Reduced AA turnover due to chronic lithium 14 may promote downregulation of COX-2 activity by a posttranscriptional or post-translational mechanism, or lithium may affect transcription or translation of COX-2 in another way. COX-2 mRNA has 'AUUUA' motifs in its 3Ј-untranslated region (3Ј-UTR) 36 that confer post-transcriptional control of expression by acting as mRNA instability determinant or as translation inhibitory element. 37 The 3Ј-UTR of many 'unstable' messages carries motifs that may regulate translational efficiency by reversibly binding to cytosolic or nuclear factors. 38 Chronic lithium treatment, either directly or indirectly, may affect these RNA-protein interactions. Lithium's post-transcriptional effect on COX-2 could also be mediated by reduced formation of the PGE 2 that mitigates COX-2 mRNA decay and inhibition of protein translation, normally mediated by the 3Ј-UTR region of COX-2 mRNA. 39 There is limited evidence to date to link abnormal AA signaling to bipolar disorder. It has been suggested that stimulation of prostaglandin synthesis by prolactin or other hormones can contribute to mood disorders. 40 Furthermore, an allelic association has been reported between bipolar disorder in some families and pancreatic PLA 2 , 41,42 implying a role for AA. Bipolar patients may have a genetic predisposition to an abnormal circadian rhythm and sleep-wake cycle, [43] [44] [45] [46] suggesting a role for PGD 2 and PGE 2 , which are said to be involved in sleep-wake regulation. Although PGD 2 is a key eicosanoid in brain signaling and in sleep-wake regulation, its physiological action is opposite to that of PGE 2 . Indeed, when PGD synthase, the enzyme that produces PGD 2 in the brain, was inhibited by the intracerebroventricular infusion of its selective inhibitors, the amount of sleep decreased in both a time-and dosedependent manner. 45 PGE 2 , on the contrary, promotes wakefulness. 46 Since mania in bipolar subjects is accompanied by sleep reduction, 23 we focused on PGE 2 because its reduction by a pharmacological agent could normalize the sleep/wake cycle and thereby stabilize mood. This does not rule out a possible alteration in other AA metabolites, such as thromboxanes, leukotrienes, and prostacyclins.
It has been suggested that clinically relevant lithium concentrations can inhibit the synthesis of PGE 1 , a metabolite of free dihomogamma-linolenic acid and that, since PGE 1 blocks mobilization of AA, a lack of PGE 1 could be associated with AA mobilization and an excess of the 2 series PGs. 47 However, our results differ from this suggestion, as they show that AA turnover and PGE 2 are decreased by lithium. It also has been reported that lithium modulates the effects of prolactin and vasopressin on prostaglandin biosynthesis, without interfering with basal prostaglandin production. 40 
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Our results indicate that, in addition to regulating hormone-mediated prostaglandin synthesis, 40 lithium can affect the basal production of PGE 2 .
Inhibition of part of the AA cascade by lithium would be consistent with a 'functional' excess of n-6 (eg, AA) compared with n-3 PUFAs (eg, docosahexaenoic acid) contributing to bipolar disorder. Supporting this interpretation is evidence that dietary n-3 PUFA supplementation was beneficial in patients with bipolar disorder, 48 and that seafood consumption, a measure of n-3 PUFA intake, correlated with a lower prevalence of bipolar disorder in a cross-national epidemiological study. 49 The ratio of n-3 to n-6 PUFAs can modulate a number of functionally relevant cellular processes, including PUFA elongation and desaturation, PUFA distribution among complex lipids, and conversion of AA to prostaglandins by COX-2, the latter being inhibited by docosahexaenoic acid. [50] [51] [52] In summary, we have shown that chronic lithium, in addition to reducing AA turnover in rat brain phospholipids, downregulates AA conversion to PGE 2 by COX-2. This effect could contribute to lithium's therapeutic action in bipolar disorder. Although care must be paid in extrapolating data from rodents to a complex human psychiatric disorder, if COX-2 and PGE 2 were found to be increased in postmortem brain or in cerebrospinal fluid from bipolar patients, COX-2 inhibitors could represent a new therapeutic approach for the treatment of this disease.
